Targeting the mevalonate pathway in multiple myeloma

Leukemia Research

Volumn 34, Issue 3, 2010, Pages 267-268

  Van der Spek, Ellen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

FPP; GGPP; Mevalonate pathway; Multiple myeloma; Plasma cell lines

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; BENDAMUSTINE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; K RAS PROTEIN; MEVALONIC ACID; PAMIDRONIC ACID; SIMVASTATIN; VINCRISTINE;

APOPTOSIS; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DRUG MEGADOSE; EDITORIAL; ENZYME INHIBITION; HUMAN; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING;

ANIMALS; HUMANS; MEVALONIC ACID; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION;

EID: 77649179772     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.027     Document Type: Editorial

References (23)

1. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
2. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
3. van de Donk N.W., Kamphuis M.M., van Kessel B., Lokhorst H.M., Bloem A.C. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003, 102:3354-3362.
4. Cafforio P., Dammacco F., Gernone A., Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005, 26:883-891.
5. Osadchy A., Drucker L., Radnay J., Shapira H., Lishner M. Microenvironment factors do not afford myeloma cell lines protection from simvastatin. Eur J Haematol 2004, 73:183-190.
6. Schmidmaier R., Baumann P., Simsek M., Dayyani F., Emmerich B., Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004, 104(6):1825-1832.
7. Hentosh P., Yuh S.H., Elson C.E., Peffley D.M. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 2001, 32:154-166.
8. van de Donk N.W., Kamphuis M.M., Lokhorst H.M., Bloem A.C. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002, 16:1362-1371.
9. Schmidmaier R., Simsek M., Baumann P., Emmerich B., Meinhardt G. Synergistic antimyeloma effects of zoledronate and simvastatin. Anticancer Drugs 2006, 17:621-629.
10. Morgan M.A., Sebil T., Aydilek E., Peest D., Ganser A., Reuter C.W. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol 2005, 130(6):912-925.
11. Dai Y., Khanna P., Chen S., Pei X.Y., Dent P., Grant S. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 2007, 109(10):4415-4423.
12. van der Spek E., Bloem A.C., Lokhorst H.M., van Kessel B., Bogers-Boer L., van de Donk N.W. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 2008.
13. Ural A.U., Yilmaz M.I., Avcu F., Pekel A., Zerman M., Nevruz O., et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003, 78(5):443-449.
14. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G., Croucher P.I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997, 98:665-672.
15. Bolick S.C., Landowski T.H., Boulware D., Oshiro M.M., Ohkanda J., Hamilton A.D., et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 2003, 17(2):451-457.
16. Schmidmaier R., Baumann P., Bumeder I., Meinhardt G., Straka C., Emmerich B. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007, 79(3):240-243.
17. Hamadani M., Hade E., Benson D.M., Hofmeister C.C. The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. Biol Blood Marrow Transplant 2008, 14:351-352.
18. van der Spek E., Bloem A.C., Sinnige H.A., Lokhorst H.M. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica 2007, 92:e130-e131.
19. Landgren O., Zhang Y., Zahm S.H., Inskip P., Zheng T., Baris D. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 2006, 15(12):2342-2347.
20. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996, 334(8):488-493.
21. Attal M., Harousseau J.L., Leyvraz S., Doyen C., Hulin C., Benboubker L., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108(10):3289-3294.
22. Alsina M., Fonseca R., Wilson E.F., Belle A.N., Gerbino E., Price-Troska T., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004, 103(9):3271-3277.
23. Wong W.W., Clendening J.W., Martirosyan A., Boutros P.C., Bros C., Khosravi F., et al. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther 2007, 6(6):1886-1897.